Fulvestrant Formulation Using DMSO and Triglycerides to Reduce Injection Pain

Solution Overview

Problem

Current fulvestrant injection formulations, particularly FASLODEX, are painful due to the use of castor oil, causing skin irritation, allergic reactions, and gastrointestinal disturbances, and lack long-term stability, necessitating a formulation without castor oil and improved stability.

Innovation Solution

Fulvestrant compositions incorporating dimethyl sulfoxide (DMSO), glycofurol, caprylic and capric triglycerides, and benzyl benzoate or benzyl alcohol, with a solvent: oil mixture: sustained release member volume ratio of 1-2.5:0.9-2.5:0.9-2.5, providing concentrations from 50 mg/ml to 150 mg/ml and achieving long-term stability with reduced impurities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If castor oil is used as a formulation vehicle, then fulvestrant can be delivered effectively, but the injection becomes extremely painful and causes skin irritation, allergic reactions, and gastrointestinal disturbances

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent removes castor oil from the formulation entirely and replaces it with a novel vehicle system comprising dimethyl sulfoxide (DMSO) as the primary solvent, combined with specific oils (medium-chain triglycerides, castor oil-free alternatives) and sustained release agents. This extraction of the harmful substance while maintaining therapeutic efficacy through alternative vehicles directly resolves the contradiction between effective drug delivery and avoidance of painful side effects

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the chemical and physical parameters of the formulation vehicle from castor oil-based to a multi-component system with DMSO (20-60% v/v), specific oils (30-60% v/v), and sustained release agents (10-40% w/v). This parameter change in composition fundamentally alters the injection characteristics, reducing pain and irritation while maintaining fulvestrant solubility and delivery efficacy

Inventive Principle:
Principle #35Parameter changes

2Stability of the object's composition

If castor oil derivatives are included in the formulation, then drug stability may be maintained, but long-term stability is insufficient and impurities increase over time

Engineering Contradiction:
Core Design Contradiction:
Stability of the object's compositionVSDuration of action of stationary object

Solution Approach 1:

The patent employs a composite formulation system combining DMSO (solvent), specific oils (stability enhancers), and sustained release agents (release control). This composite material approach creates synergistic effects that simultaneously provide short-term stability during storage and long-term stability over 24+ months, while the sustained release agents control drug release kinetics to prevent impurity formation over time

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The sustained release agents in the formulation act as intermediaries between the fulvestrant drug and the biological system, controlling the release rate and preventing premature degradation. These intermediaries (sustained release agents) mediate the drug's stability profile, ensuring both short-term and long-term stability while minimizing impurity generation during storage and administration

Inventive Principle:
Principle #24Intermediary (Mediator)

3Ease of manufacture

If castor oil is used as the base, then the formulation can be prepared simply, but the injection volume must be large and pain is increased

Engineering Contradiction:
Core Design Contradiction:
Ease of manufactureVSVolume of moving object

Solution Approach 1:

The patent changes the concentration parameter of fulvestrant in the formulation from typical levels to highly concentrated formulations (50-150 mg/ml). This parameter change in concentration allows for significantly reduced injection volumes (e.g., 0.5-2 ml instead of larger volumes) while maintaining or enhancing therapeutic efficacy. The novel vehicle system enables achieving these high concentrations without the pain and irritation associated with castor oil

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

By removing castor oil from the formulation, the patent eliminates the substance that causes pain and necessitates larger volumes for effective delivery. The alternative vehicle system achieves better solubility and delivery efficiency, allowing concentrated formulations in smaller, less painful volumes while maintaining ease of manufacture through straightforward preparation procedures

Inventive Principle:
Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulations are substantially free of castor oil derivatives, exhibit improved long-term stability with less than 5% total impurities after 24 months, and achieve steady-state concentrations for extended periods, reducing pain and improving administration efficacy.

Implementation Method 1

a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof

Methodology Applied
Scientific EffectSolvation: Solvation

Implementation Method 2

an oil mixture selected from i) caprylic and capric triglycerides; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid and benzyl alcohol

Methodology Applied
Scientific EffectSustained release:

Data Source

PatentEP2836199B1Fulvestrant formulations
Publication Date: 2024.06.19
  • EP2836199B1 patent drawingFigure 1
  • EP2836199B1 patent drawingFigure 2
  • EP2836199B1 patent drawing

AI summary

Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response ("PAR") basis as determined by high performance liquid chromatography ("HPLC") at a wavelength of 223nm, after at least about 24 months of storage at a temperature of from about 5 °C to about 25 °C.